Get the app
US › Healthcare

MeiraGTx Holdings PLC (MGTX)

US · Healthcare · Biotechnology

$9.28-6.17%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$321.4M
Revenue YoY
+8608.6%
Net profit
$160.7M
EPS
$1.71
EPS estimate
$-0.39
Net margin
50.0%

EPS came in at 1.71 against a street estimate of -0.39 — a beat of 538.5%.

Key statistics

Market cap
$891.3M
P/E
10.7
Forward P/E
64.1
P/B
5.23
Book value
$2.29
EPS (TTM)
$0.87
52-week high
$15.35
52-week low
$6.62
50-day MA
$12.51
200-day MA
$10.21
Beta
1.35

Analyst view

Analysts rate MeiraGTx Holdings PLC a strong buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $27.75.

Shareholding

Insiders
16.33%
Institutions
70.71%

Largest institutional holders

FundStake
Sanofi12.70%
Perceptive Advisors LLC11.23%
Rubric Capital Management LP9.47%
Johnson & Johnson6.91%
BlackRock Inc4.95%
Adage Capital Partners Gp LLC4.58%
Opaleye Management Inc3.70%
Millennium Management LLC3.09%

Recent filings & reports

DocumentDate
Board / officer change · Q3 2026
MEIRAGTX HOLDINGS PLC – FORM 8-K SUMMARY September 22, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Company: MeiraGTx Holdings plc, a biopharmaceutical
2026-09-23
Quarterly report · Q2 2026
MEIRAGTX HOLDINGS PLC – Q2 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash and cash equivalents increased to $143.2 million as of June 30,
2026-08-13
Results announced · Q3 2026
MEIRAGTX HOLDINGS PLC – Q2 2026 FINANCIAL & OPERATIONAL SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $143.2 million as of June 30, 2026 (vs
2026-08-13
Material agreement · Q2 2026
MEIRAGTX HOLDINGS PLC – FORM 8-K SUMMARY As of June 30, 2026 --- HEADLINE NUMBERS • Royalty Note financing: Up to $375 million in total commitments
2026-07-07
Shareholder vote results · Q2 2026
MEIRAGTX HOLDINGS PLC – DOCUMENT SUMMARY HEADLINE NUMBERS • Annual General Meeting held on June 11, 2026 • 75,326,022 ordinary shares present in per
2026-06-15
Quarterly report · Q1 2026
MEIRAGTX HOLDINGS PLC - Q1 2026 SUMMARY HEADLINE NUMBERS • Cash position: $71.5 million at March 31, 2026 (up from $65.9 million at December 31, 202
2026-05-14
Results announced · Q2 2026
MEIRAGTX Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Net loss for Q1 2026: $46.3 million ($0.57 per share) vs. $40.0 million ($0.51 per
2026-05-14
Proxy statement · Q2 2026
MEIRAGTX HOLDINGS PLC – 2026 PROXY STATEMENT SUMMARY CEO COMPENSATION & CHANGE • CEO total compensation figure not disclosed in provided document ex
2026-04-30

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for MeiraGTx Holdings PLC — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Data updated 2026-10-19.